Evidence map›Paper›PMID 23281739›Full record

ArticleBMC genomics2012

Comprehensive analysis of microRNAs in breast cancer.

Hong-Tai Chang, Sung-Chou Li, Meng-Ru Ho, Hung-Wei Pan, Luo-Ping Ger, Ling-Yueh Hu, Shou-Yu Yu, Wen-Hsiung Li, Kuo-Wang Tsai

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine.International journal of molecular sciences · 2021
    Article
  7. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.Journal of experimental & clinical cancer research : CR · 2018
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Regulation of the mRNA half-life in breast cancer.World journal of clinical oncology · 2014
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Hong-Tai ChangDepartment of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic of China.
Sung-Chou Li
Meng-Ru Ho
Hung-Wei Pan
Luo-Ping Ger
Ling-Yueh Hu
Shou-Yu Yu
Wen-Hsiung Li
Kuo-Wang Tsai
Kaohsiung Veterans General Hospital · TWBiodiversity Research Center, Academia Sinica · TWGenomics Research Center, Academia Sinica · TWInstitute of Biomedical Sciences, Academia Sinica · TWUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) are short noncoding RNAs (approximately 22 nucleotides in length) that play important roles in breast cancer progression by downregulating gene expression. The detailed mechanisms and biological functions of miRNA molecules in breast carcinogenesis have yet to be fully elucidated. This study used bioinformatics and experimental approaches to conduct detailed analysis of the dysregulated miRNAs, arm selection preferences, 3' end modifications, and position shifts in isoforms of miRNAs (isomiRs) in breast cancer.

methodsNext-generation sequencing (NGS) data on breast cancer was obtained from the NCBI Sequence Read Archive (SRA). The miRNA expression profiles and isomiRs in normal breast and breast tumor tissues were determined by mapping the clean reads back to human miRNAs. Differences in miRNA expression and pre-miRNA 5p/3p arm usage between normal and breast tumor tissues were further investigated using stem-loop reverse transcription and real-time polymerase chain reaction.

resultsThe analysis identified and confirmed the aberrant expression of 22 miRNAs in breast cancer. Results from pathway enrichment analysis further indicated that the aberrantly expressed miRNAs play important roles in breast carcinogenesis by regulating the mitogen-activated protein kinase (MAPK) signaling pathway. Data also indicated that the position shifts in isomiRs and 3' end modifications were consistent in breast tumor and adjacent normal tissues, and that 5p/3p arm usage of some miRNAs displayed significant preferences in breast cancer.

conclusionsExpression pattern and arm selection of miRNAs are significantly varied in breast cancers through analyzing NGS data and experimental approach. These miRNA candidates have high potential to play critical roles in the progression of breast cancer and could potentially provide as targets for future therapy.

Indexed as

3' Untranslated Regions5' Untranslated RegionsBreast NeoplasmsDatabases, GeneticFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMAP Kinase Signaling SystemMicroRNAsMitogen-Activated Protein Kinases3' Untranslated Regions5' Untranslated RegionsMicroRNAsMitogen-Activated Protein Kinases

Identifiers

PMID23281739
PMCPMC3521236
OpenAlexW2163370258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.